Skip to main content

Surgical treatment of prolactinomas: cons

Endocrine volume 47, pages 730–733 (2014)Cite this article

Abstract

Prolactinomas account for approximately 40 % of all pituitary adenomas. Over 95 % of prolactinomas are microadenomas (< 10 mm diameter). Treatment is indicated to correct hypogonadism, restore other hormonal deficits, and alleviate local mass effects. Dopamine agonists (DA) are highly effective in achieving these goals and are well-tolerated. The vast majority of prolactinomas will respond to conventional doses of cabergoline (≤2 mg/week) that do not carry an increased risk of cardiac valvular abnormalities. DA therapy may be successful withdrawn in a subset of patients and thus is not necessarily a lifelong commitment. Although transsphenoidal surgery (TSS) is an option for prolactinoma treatment, it is less effective than medical management, carries considerably more risk, and is more expensive. The benefit/risk ratio for DA therapy compared to TSS actually becomes increasingly more favorable as tumor size increases. Therefore DA should remain the clear treatment of choice for essentially all patients with prolactinomas, reserving TSS as a second-line option for the very small number of patients that do not tolerate or are completely resistant to DA therapy.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. A.F. Daly, M.A. Tichomirowa, A. Beckers, The epidemiology and genetics of pituitary adenomas. Best Pract. Res. Clin. Endocrinol. Metab. 23(5), 543–554 (2009). doi:10.1016/j.beem.2009.05.008

    CAS  PubMed  Article  Google Scholar 

  2. A. Ciccarelli, A.F. Daly, A. Beckers, The epidemiology of prolactinomas. Pituitary 8(1), 3–6 (2005). doi:10.1007/s11102-005-5079-0

    PubMed  Article  Google Scholar 

  3. A. Fernandez, N. Karavitaki, J.A. Wass, Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. 72(3), 377–382 (2010). doi:10.1111/j.1365-2265.2009.03667.x

    Article  Google Scholar 

  4. M.P. Gillam, M.E. Molitch, Prolactinoma, in The Pituitary, 3rd edn, ed. by S. Melmed (Elsevier Inc., San Diego, 2011), pp. 475–531

  5. J. Webster, G. Piscitelli, A. Polli, C.I. Ferrari, I. Ismail, M.F. Scanlon, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N. Engl. J. Med. 331(14), 904–909 (1994). doi:10.1056/NEJM199410063311403

    CAS  PubMed  Article  Google Scholar 

  6. V. Pascal-Vigneron, G. Weryha, M. Bosc, J. Leclere, Hyperprolactinemic amenorrhea: treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study. Presse Med. 24(16), 753–757 (1995)

    CAS  PubMed  Google Scholar 

  7. A. Colao, A. Di Sarno, F. Sarnacchiaro, D. Ferone, G. Di Renzo, B. Merola, L. Annunziato, G. Lombardi, Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J. Clin. Endocrinol. Metab. 82(3), 876–883 (1997). doi:10.1210/jcem.82.3.3822

    CAS  PubMed  Article  Google Scholar 

  8. Dekkers OM, Lagro J, Burman P, et al., Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 95, 43–51 (2010)

  9. E. Delgrange, T. Daems, J. Verhelst, R. Abs, D. Maiter, Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur. J. Endocrinol. 160(5), 747–752 (2009). doi:10.1530/EJE-09-0012

    CAS  PubMed  Article  Google Scholar 

  10. M. Ono, N. Miki, T. Kawamata, R. Makino, K. Amano, T. Seki, O. Kubo, T. Hori, K. Takano, Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J. Clin. Endocrinol. Metab. 93(12), 4721–4727 (2008). doi:10.1210/jc.2007-2758

    CAS  PubMed  Article  Google Scholar 

  11. G. Simonis, J.T. Fuhrmann, R.H. Strasser, Meta-analysis of heart valve abnormalities in parkinson’s disease patients treated with dopamine agonists. Mov. Disord. 22(13), 1936–1942 (2007). doi:10.1002/mds.21639

    PubMed  Article  Google Scholar 

  12. M.E. Molitch, Management of medically refractory prolactinoma. J. Neurooncol. 117(3), 421–428 (2014). doi:10.1007/s11060-013-1270-8

    PubMed  Article  Google Scholar 

  13. E. Valassi, A. Klibanski, B.M. Biller, Clinical Review#: potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J. Clin. Endocrinol. Metab. 95(3), 1025–1033 (2010). doi:10.1210/jc.2009-2095

    CAS  PubMed  Article  Google Scholar 

  14. R. Zanettini, A. Antonini, G. Gatto, R. Gentile, S. Tesei, G. Pezzoli, Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Cardiovasc. Ther. 29(6), 404–410 (2011). doi:10.1111/j.1755-5922.2010.00169.x

    CAS  PubMed  Article  Google Scholar 

  15. J. Kharlip, R. Salvatori, G. Yenokyan, G.S. Wand, Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J. Clin. Endocrinol. Metab. 94(7), 2428–2436 (2009). doi:10.1210/jc.2008-2103

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  16. A.T. Faje, A. Klibanski, The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: cons. Endocrine (2014). doi:10.1007/s12020-014-0308-9

    PubMed  Google Scholar 

  17. F.G. Barker 2nd, A. Klibanski, B. Swearingen, Transsphenoidal surgery for pituitary tumors in the United States, 1996–2000: mortality, morbidity, and the effects of hospital and surgeon volume. J. Clin. Endocrinol. Metab. 88(10), 4709–4719 (2003). doi:10.1210/jc.2003-030461

    CAS  PubMed  Article  Google Scholar 

  18. B. Swearingen, Update on pituitary surgery. J. Clin. Endocrinol. Metab. 97(4), 1073–1081 (2012). doi:10.1210/jc.2011-3237

    CAS  PubMed  Article  Google Scholar 

  19. V. Primeau, C. Raftopoulos, D. Maiter, Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur. J. Endocrinol. 166(5), 779–786 (2012). doi:10.1530/EJE-11-1000

    CAS  PubMed  Article  Google Scholar 

  20. D.K. Hamilton, M.L. Vance, P.T. Boulos, E.R. Laws, Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 8(1), 53–60 (2005). doi:10.1007/s11102-005-5086-1

    PubMed  Article  Google Scholar 

  21. E.R. Laws Jr, K. Thapar, Pituitary surgery. Endocrinol. Metab. Clin. North. Am. 28(1), 119–131 (1999).

  22. N. Sudhakar, A. Ray, J.A. Vafidis, Complications after trans-sphenoidal surgery: our experience and a review of the literature. Br. J. Neurosurg. 18(5), 507–512 (2004)

    CAS  PubMed  Google Scholar 

  23. P.B. Nelson, M. Goodman, J.C. Maroon, A.J. Martinez, J. Moossy, A.G. Robinson, Factors in predicting outcome from operation in patients with prolactin-secreting pituitary adenomas. Neurosurgery 13(6), 634–641 (1983)

    CAS  PubMed  Article  Google Scholar 

  24. M.E. Molitch, Prolactinoma in pregnancy. Best Pract. Res. Clin. Endocrinol. Metab. 25(6), 885–896 (2011). doi:10.1016/j.beem.2011.05.011

    CAS  PubMed  Article  Google Scholar 

  25. J.E. Tyson, P. Hwang, H. Guyda, H.G. Friesen, Studies of prolactin secretion in human pregnancy. Am. J. Obstet. Gynecol. 113(1), 14–20 (1972)

    CAS  PubMed  Google Scholar 

  26. S. Biswas, C.H. Rodeck, Plasma prolactin levels during pregnancy. Br. J. Obstet. Gynaecol. 83(9), 683–687 (1976)

    CAS  PubMed  Article  Google Scholar 

  27. R. Cohen-Kerem, C. Railton, D. Oren, M. Lishner, G. Koren, Pregnancy outcome following non-obstetric surgical intervention. Am. J. Surg. 190(3), 467–473 (2005). doi:10.1016/j.amjsurg.2005.03.033

    PubMed  Article  Google Scholar 

  28. N.F. Marko, E. LaSota, A.H. Hamrahian, R.J. Weil, Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly. J. Neurosurg. 117(3), 522–538 (2012). doi:10.3171/2012.4.JNS11739

    PubMed  Article  Google Scholar 

  29. C.G. Patil, S.P. Lad, G.R. Harsh, E.R. Laws Jr, M. Boakye, National trends, complications, and outcomes following transsphenoidal surgery for Cushing’s disease from 1993 to 2002. Neurosurg. Focus 23(3), 7 (2007). doi:10.3171/foc.2007.23.3.9

    Google Scholar 

  30. A.S. Little, K. Chapple, H. Jahnke, W.L. White, Comparative inpatient resource utilization for patients undergoing endoscopic or microscopic transsphenoidal surgery for pituitary lesions. J. Neurosurg. (2014). doi:10.3171/2014.2.JNS132095

    PubMed  Google Scholar 

Download references

Conflict of interest

All medications discussed are currently generic. However, MEM has received research support in the past from Novartis and Pfizer for the conduct of studies with bromocriptine and cabergoline.

Author information

Affiliations

  1. Division of Endocrinology, Metabolism and Molecular Medicine, Feinberg School of Medicine, Northwestern University, 645 N. Michigan Ave., Suite 530, Chicago, IL, 60611, USA

    Eve Bloomgarden & Mark E. Molitch

Authors
  1. Eve Bloomgarden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark E. Molitch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark E. Molitch.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bloomgarden, E., Molitch, M.E. Surgical treatment of prolactinomas: cons. Endocrine 47, 730–733 (2014). https://doi.org/10.1007/s12020-014-0369-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-014-0369-9

Keywords

  • Prolactinoma
  • Pituitary
  • Bromocriptine
  • Cabergoline
  • Transsphenoidal surgery
  • Prolactin